Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Core document on erectile dysfunction: key aspects in the care of a patient with erectile dysfunction

Abstract

The aim of this Core Document of the Spanish Consensus on Erectile dysfunction (ED) is to offer guidance to the nonspecialist physician in the management of patients with ED. ED is one of the most frequent chronic health problems in men older than 40 y of age and may also act as a sentinel symptom for other important underlying diseases. Its etiology can be classified into organic, psychogenic, or mixed. In most cases, the underlying cause of ED is usually a chronic health problem (such as diabetes, hypertension, atherosclerosis, and so on) or an adverse drug effect. The initial step in the management is to assess erectile function in patients with risk factors for ED. Once ED has been established, a detailed sexual, medical, and social history, including a review of medications used, is the most important aspect of a patient's assessment. Generally, examination should be limited to the cardiovascular, neurological, and urogenital systems. Fasting glucose and blood lipid profile should be performed in every man with ED, and free testosterone levels in men older than 50 y or if hypogonadism is suspected; other diagnostic tests are optional and should be requested on an individualized basis. In many cases, the most likely cause of ED can be identified based on the above information. Therapeutic intervention should be patient-oriented and based on the expectations and wishes of the patient and his partner, who should be included in discussions whenever possible. Basic interventions common to any type of ED include sexual counseling, lifestyle modifications, treatment of associated medical conditions, and switching to alternative drugs with lower risk of ED. In certain cases, an etiologic treatment may be performed (sex therapy, revascularization surgery, and hormonal therapy). Most patients with ED will benefit from symptomatic treatments; first-line therapy may be prescribed by physicians who are not specialists in ED, and includes oral agents such as inhibitors of phosphodiesterase type 5, currently considered the drugs of choice for initial treatment of ED. Intracavernous drugs are the second-line therapy, and surgical treatments, such as implantation of penile prostheses, are reserved for urologists/andrologists who specialize in ED. Referral may be appropriate where indicated by age, clinical findings, or the patient's request.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. Feldman HA et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54–61.

    Article  CAS  PubMed  Google Scholar 

  2. Althof SE . Quality of life and erectile dysfunction. Urology 2002; 59: 803–810.

    Article  PubMed  Google Scholar 

  3. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993; 270: 83–90.

  4. Guideline for the investigation and management of erectile dysfunction. Alberta Medical Association, 1630008, Edmonton, AB, June 2001, p 9.

  5. Martin-Morales A et al. Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiologia de la Disfuncion Erectil Masculina Study. J Urol 2001; 166: 569–574, discussion 574–575.

    Article  CAS  PubMed  Google Scholar 

  6. Benet AE, Melman A . The epidemiology of erectile dysfunction. Urol Clin N Am 1995; 22: 699–709.

    CAS  Google Scholar 

  7. McCulloch DK et al. The prevalence of diabetic impotence. Diabetologia 1980; 18: 279–283.

    Article  CAS  PubMed  Google Scholar 

  8. Fedele D et al. Erectile dysfunction in type 1 and type 2 diabetics in Italy. On behalf of Gruppo Italiano Studio Deficit Erettile nei Diabetici. Int J Epidemiol 2000; 29: 524–531.

    Article  CAS  PubMed  Google Scholar 

  9. Nathan DM, Singer DE, Godine JE, Perlmuter LC . Non-insulin-dependent diabetes in older patients. Complications and risk factors. Am J Med 1986; 81: 837–842.

    Article  CAS  PubMed  Google Scholar 

  10. DeWire DM . Evaluation and treatment of erectile dysfunction. Am Fam Physician 1996; 53: 2101–2108.

    CAS  PubMed  Google Scholar 

  11. Jensen J et al. The prevalence and etiology of impotence in 101 male hypertensive outpatients. Am J Hypertens 1999; 12: 271–275.

    Article  CAS  PubMed  Google Scholar 

  12. Cuellar de Leon AJ et al. [Prevalence erectile dysfunction in patients with hypertension]. Med Clin (Barc) 2002; 119: 521–526.

    Article  Google Scholar 

  13. Rosen MP et al. Cigarette smoking: an independent risk factor for atherosclerosis in the hypogastric-cavernous arterial bed of men with arteriogenic impotence. J Urol 1991; 145: 759–763.

    Article  CAS  PubMed  Google Scholar 

  14. Keene LC, Davies PH . Drug-related erectile dysfunction. Adverse Drug React Toxicol Rev 1999; 18: 5–24.

    CAS  PubMed  Google Scholar 

  15. Rosen RC et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822–830.

    Article  CAS  PubMed  Google Scholar 

  16. Rosen RC et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 319–326.

    Article  CAS  PubMed  Google Scholar 

  17. Miller TA . Diagnostic evaluation of erectile dysfunction. Am Fam Physician 2000; 61: 95–104, 109–110.

    CAS  PubMed  Google Scholar 

  18. Ralph D, McNicholas T . UK management guidelines for erectile dysfunction. BMJ 2000; 321: 499–503.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Jeremy JY, Mikhailidis DP . Cigarette smoking and erectile dysfunction. J R Soc Health 1998; 118: 151–155.

    Article  CAS  Google Scholar 

  20. Derby CA et al. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology 2000; 56: 302–306.

    Article  CAS  PubMed  Google Scholar 

  21. Jardin A, Wagner G, Khouri Sea. Recommendations of the 1st International Consultation on Erectile Dysfunction. In: Jardin A, Wagner G, Khouri S, Giuliano F, Padma-Nathan H, Rosen R (eds). Erectile Dysfunction. Health Publication Ltd: Plymouth UK, 2000, pp 709–726.

    Google Scholar 

  22. Greiner KA, Weigel JW . Erectile dysfunction [see comments]. Am Fam Physician 1996; 54: 1675–1682.

    CAS  PubMed  Google Scholar 

  23. Goldstein I et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397–1404.

    Article  CAS  PubMed  Google Scholar 

  24. Morales A et al. Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction. Int J Impot Res 1998; 10: 69–74.

    Article  CAS  PubMed  Google Scholar 

  25. Boolell M, Gepi-Attee S, Gingell JC, Allen MJ . Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 1996; 78: 257–261.

    Article  CAS  PubMed  Google Scholar 

  26. Eardley I et al. Sildenafil (VIAGRA[R]), a novel oral treatment with rapid onset of action for penile erectile dysfunction [abstract]. Br J Urol 1997; 79(Suppl 4): 66.

    Google Scholar 

  27. Buvat J et al. Sildenafil (VIAGRA™), an oral treatment for erectile dysfunction: a 1-year, open-label, extension study [abstract]. J Urol 1997; 157: 204, abstract 793.

    Article  Google Scholar 

  28. Lue T . Sildenafil study group: a study of sildenafil, a new oral agent for treatment of male erectile dysfunction. J Urol 1997; 157(Suppl): 181.

    Google Scholar 

  29. Rendell MS et al. Sildenafil for treatment of erectile dysfunction in men with diabetes. JAMA 1999; 281: 421–426.

    Article  CAS  PubMed  Google Scholar 

  30. Derry F et al. Sildenafil (Viagra) a double blind, placebo-controlled, single dose, two-way crossover study in men with erectile dysfunction caused by traumatic spinal cord injury. J Urol 1997; 157(Suppl): 181.

    Google Scholar 

  31. Quirk F et al. Effect of sildenafil (VIAGRA™) on quality-of-life parameters in men with broad-spectrum erectile dysfunction. J Urol 1998; 159: 260, abstract 998.

    Google Scholar 

  32. Hatzichristou DG . Sildenafil citrate: lessons learned from 3 years of clinical experience. Int J Impot Res 2002; 14(Suppl 1): S43–S52.

    Article  PubMed  Google Scholar 

  33. Guay AT, Perez JB, Jacobson J, Newton RA . Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. J Androl 2001; 22: 793–797.

    CAS  PubMed  Google Scholar 

  34. Brotons Munto F et al. Manejo de las disfuncion erectil en atencio primaria. JANO Med Humanidades 1998; 55: 42–46.

    Google Scholar 

  35. Arruda AM, Mahoney DW, Nehra A, Pellikka PA . Cardiovascular effects of sildenafil citrate (Viagra) during exercise in patients with known or probable coronary artery disease. Presented at the Third World Congress on the Aging Male, February 7–10, 2002, Berlin, Germany.

  36. Altwein JE, Keuler FU . Oral treatment of erectile dysfunction with apomorphine SL. Urol Int 2001; 67: 257–263.

    Article  CAS  PubMed  Google Scholar 

  37. Cookson MS, Nadig PW . Long-term results with vacuum constriction device. J Urol 1993; 149: 290–294.

    Article  CAS  PubMed  Google Scholar 

  38. Rodriguez Vela L et al. Tratamiento de la disfuncion erectil mediante farmacoterapia intracavernosa. Actas Urol Esp 1998; 22: 291–319.

    CAS  PubMed  Google Scholar 

  39. Mulhall JP, Ahmed A, Branch J, Parker M . Serial assessment of efficacy and satisfaction profiles following penile prosthesis surgery. J Urol 2003; 169: 1429–1433.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to F B Brotons.

Appendices

Appendix A

International Index of Erectile Function (IIEF) (See Table A1)

Table 5 Table a1

Appendix B

Sexual Health Inventory for Men (SHIM) (See Table A2)

Table 6 Table a2

Appendix C

Decision Algorithm for Patients With Erectile Dysfunction (See Table A3)

Table 7 Table a3

Appendix D

Referral Algorithm for Patients With Erectile Dysfunction (See Table A4)

Table 8 Table a4

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Brotons, F., Campos, J., Gonzalez-Correales, R. et al. Core document on erectile dysfunction: key aspects in the care of a patient with erectile dysfunction. Int J Impot Res 16 (Suppl 2), S26–S39 (2004). https://doi.org/10.1038/sj.ijir.3901240

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901240

Keywords

  • erectile dysfunction

This article is cited by

Search

Quick links